Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
WuXi Biologics (Cayman) Inc.
WuXi Biologics is a contract manufacturer that helps drug companies discover, develop, and mass-produce biologic medicines.
WuXi Biologics is a contract research, development, and manufacturing organization — a CDMO, in industry shorthand — for biologic drugs. Biologics are medicines made from living cells rather than simple chemicals: things like antibodies and other protein-based therapies that treat cancer, autoimmune diseases, and other serious conditions. WuXi Biologics does not invent and sell its own brand-name drugs. Instead, it does the lab science and factory work for other companies that do.
The business runs across the full life of a drug. Early on, WuXi Biologics helps customers discover and engineer a molecule and run the lab and animal testing needed to push it toward human trials. Then it develops a reliable manufacturing process and makes the clinical-trial batches a drug needs before approval. Once a drug wins approval, the company keeps making it at commercial scale. This full-chain service is the point: a biotech startup with a promising idea but no factory can hand the whole problem to WuXi and focus on the science and the money. The customers are the engine. They include big global pharmaceutical companies and, importantly, a long tail of small and mid-sized biotechs, often in the US and Europe, that have ideas but no manufacturing muscle. Customers pick a CDMO partly on cost and speed, but mostly on trust and track record — switching a manufacturer mid-stream is painful and risky. That stickiness is the moat: once WuXi Biologics is embedded in a drug's development, it tends to stay for that drug's commercial life. The company has grown fast by riding a global boom in biologics and by building capacity in China, Ireland, Germany, and the US to serve customers closer to home.
There are real risks, and they are not small. WuXi Biologics depends heavily on customers in the US and Europe, and it has been swept into geopolitical tension over whether American drugmakers should rely on Chinese contractors; proposed US legislation aimed at certain Chinese biotech firms has rattled investors even though the company itself has disputed the concerns. Competition is fierce too, from global players like Lonza and Samsung Biologics and from other Chinese CDMOs. A single major customer loss or a regulatory or political blow can move the stock sharply. The core bet is simple: as more of the world's medicines become biologics, someone has to make them, and WuXi Biologics wants to be the default someone.
Saved answer · last researched 12 Nov 2026
BIG PICTURE
More than 60% of WuXi Biologics' revenue comes from North American drugmakers
- 60% North America
- 40% Rest of the world
WuXi Biologics is a Chinese company, but most of its customers are in North America. More than 60% of revenue comes from US companies, which hand it the messy, specialized work of turning a molecule into a medicine that can be made by the million. That reliance cuts both ways. It pays the bills, and it puts the business in the path of any political fight over where drugs get made. Source: Morningstar, data from 2024
Timeline
A Biologics Unit Inside WuXi
WuXi started as a company that helped others make medicines the traditional way, with chemistry. Around 2010 it planted a seed for a different kind of drug: biologics, the big molecules grown in living cells rather than cooked up in a lab. That small in-house unit, incorporated in the Chinese city of Wuxi, did the whole job for drugmakers, from early discovery to development to manufacturing. For a few years it was just one business line among many, but it was quietly becoming the foundation for something much bigger.
One Company Splits Into Three
By 2015, WuXi's parent decided its collection of businesses had outgrown one roof. It split itself into three pieces, separating the small-molecule work, the small-molecule manufacturing, and the biologics unit. The biologics arm walked out as its own company, free to chase its own investors and reward its own managers. From then on it had one clear job: making large-molecule biologic drugs for other companies, and nothing else.
First Biologics Stock in Hong Kong
A couple of years later, the newly independent company went public in Hong Kong and made history as the first biologics outsourcer listed there, earning it a nickname as the first biologics stock. Investors loved the story. The company's market value jumped from roughly thirty billion Hong Kong dollars to nearly a hundred billion within a year. For a business that made its money doing other people's manufacturing, that was a startling amount of enthusiasm.
A Pandemic Windfall
Then the pandemic arrived, and WuXi Biologics found itself at the center of the global scramble for COVID-19 treatments and vaccines. The first half of 2021 was explosive: revenue more than doubled and profit grew even faster. The company had a simple strategy it called win-the-molecule, meaning it tried to grab a drug project early and hold on as the drug moved through testing toward market. That strategy, plus a pile of COVID-related contracts, pushed its total projects past four hundred, including several in late-stage trials and commercial manufacturing.
The Guidance Cut That Stung
The fast years could not last forever. Early in 2024, the company abruptly slashed its own growth forecast from about thirty percent down to ten, blaming a funding drought among biotech startups and weaker demand. Investors were stunned, and the stock fell by a third in a single week, wiping out billions in market value. The CEO called it the hardest year in the company's history. The long run of explosive growth was over, and the question now was what came next.
Washington Starts Asking Questions
Around the same time, a new kind of risk appeared that had nothing to do with customers or factories. A U.S. Senate hearing in March 2024 focused on a proposed law aimed at Chinese biotech firms, and WuXi Biologics was among the names in the spotlight. The company insisted it posed no national security risk and said it would keep watching how things developed. But from then on, politics became a regular source of stock swings and forced the company to think hard about its future.
The Biosecure Act Lands Softly
For a while, the worst-case fear was that America would simply ban its government from doing business with WuXi Biologics. When the law finally passed in late 2025 as part of a defense spending bill, the company was not named directly; the burden shifted to the White House to draw up a list of companies of concern. That meant WuXi was not automatically barred from federal contracts, and the immediate threat faded. A cloud that had hung over the stock for nearly two years had finally thinned, without fully disappearing.
Buying Dongyao
With the political scare easing, the company turned back to building. In early 2026, WuXi Biologics and its joint venture WuXi XDC launched a cash offer for Dongyao Pharmaceuticals, paying a huge premium to win over shareholders. The point was capacity and reach: more manufacturing space in China, more drug projects, more customers, and a stronger hand in the fast-growing field of antibody-drug conjugates, a kind of targeted cancer therapy. If the deal closed, Dongyao would become part of the family and its numbers folded into the group's own.
A Record Backlog
The payoff showed up in the numbers. In the first half of 2026, revenue climbed about eighteen percent and adjusted profit grew much faster, with margins improving. Even better, the company's order book, the work already signed but not yet delivered, stood at more than twenty-five billion dollars, roughly eight times what it earned in a full year. That gave it rare visibility into the future. It also added a record number of new projects and raised its own growth target for the year, a striking turnaround from the grim guidance cut two years earlier.